{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:58:05Z","timestamp":1792803485335,"version":"4.5.0"},"reference-count":61,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>The immune system is a complex network of multiple cells, tissues, and organs that protects the body against foreign pathogenic invaders. However, the immune system may mistakenly attack healthy cells and tissues due to the cross-reactivity of anti-pathogen immunity, leading to autoimmunity by autoreactive T cells and\/or autoantibody-secreting B cells. Autoantibodies can accumulate, resulting in tissue or organ damage. The neonatal crystallizable fragment receptor (FcRn) is an important factor in immune regulation through controlling the trafficking and recycling of immunoglobulin G (IgG) molecules, the most abundant antibody in humoral immunity. In addition to its role in IgG trafficking and recycling, FcRn is also involved in antigen presentation, which is a crucial step in the activation of the adaptive immune response via directing the internalization and trafficking of antigen-bound IgG immune complexes into compartments of degradation and presentation in antigen-presenting cells. Efgartigimod, an FcRn inhibitor, has shown promise in reducing the levels of autoantibodies and alleviating the autoimmune severity of myasthenia gravis, primary immune thrombocytopenia, and pemphigus vulgaris\/foliaceus. This article aims to provide an overview of the importance of FcRn in antigen-presenting cells and its potential as a therapeutic target in autoimmune diseases, using efgartigimod as an example.<\/jats:p>","DOI":"10.3390\/pathogens12060817","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T02:59:57Z","timestamp":1686279597000},"page":"817","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Roles of FcRn in Antigen-Presenting Cells during Autoimmunity and a Clinical Evaluation of Efgartigimod as an FcRn Blocker"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6970-065X","authenticated-orcid":false,"given":"Yihan","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-6929","authenticated-orcid":false,"given":"Shisong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford OX3 7DQ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fimmu.2013.00248","article-title":"Sweeten PAMPs: Role of Sugar Complexed PAMPs in Innate Immunity and Vaccine Biology","volume":"4","author":"Mahla","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/bs.pmbts.2014.11.014","article-title":"Chapter Nine\u2014Role of Extracellular Damage-Associated Molecular Pattern Molecules (DAMPs) as Mediators of Persistent Pain","volume":"Volume 131","author":"Price","year":"2015","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.it.2016.10.003","article-title":"Antigen Presentation to B Cells","volume":"37","author":"Heesters","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fimmu.2019.00360","article-title":"Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis","volume":"10","author":"Gaudino","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nri2527","article-title":"Antiviral Immune Responses: Triggers of or Triggered by Autoimmunity?","volume":"9","author":"Getts","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"102743","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An Updated Advance of Autoantibodies in Autoimmune Diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-Cell Tolerance Checkpoints Promote the Development of Autoimmune Diseases and Pathogenic Autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102266","DOI":"10.1016\/j.coi.2022.102266","article-title":"The Increasing Prevalence of Autoimmunity and Autoimmune Diseases: An Urgent Call to Action for Improved Understanding, Diagnosis, Treatment, and Prevention","volume":"80","author":"Miller","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The World Incidence and Prevalence of Autoimmune Diseases Is Increasing","volume":"3","author":"Lerner","year":"2016","journal-title":"Int. J. Celiac Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of Therapeutic Plasma Exchange on Immunoglobulins in Myasthenia Gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the Use of Immunoglobulin in Human Disease: A Review of Evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.3389\/fimmu.2019.03052","article-title":"Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis","volume":"10","author":"Gable","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"109474","DOI":"10.1016\/j.intimp.2022.109474","article-title":"Targeted Inhibition of FcRn Reduces NET Formation to Ameliorate Experimental Ulcerative Colitis by Accelerating ANCA Clearance","volume":"113","author":"Wen","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s13311-022-01222-x","article-title":"Therapeutic Monoclonal Antibody Therapies in Chronic Autoimmune Demyelinating Neuropathies","volume":"19","author":"Briani","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/aob-20-55","article-title":"FcRn Antagonists in ITP","volume":"6","author":"Newland","year":"2021","journal-title":"Ann. Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","article-title":"The Role of FcRn in Antigen Presentation","volume":"5","author":"Baker","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/21541248.2016.1275363","article-title":"Activation of Compensatory Pathways via Rac2 in the Absence of the Cdc42 Effector Wiskott-Aldrich Syndrome Protein in Dendritic Cells","volume":"10","author":"Baptista","year":"2017","journal-title":"Small GTPases"},{"key":"ref_19","unstructured":"Enna, S.J., and Bylund, D.B. (2007). xPharm: The Comprehensive Pharmacology Reference, Elsevier."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2567.2006.02386.x","article-title":"The Riddle of the Dual Expression of IgM and IgD","volume":"118","author":"Geisberger","year":"2006","journal-title":"Immunology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.immunol.26.021607.090248","article-title":"Mechanism and Regulation of Class Switch Recombination","volume":"26","author":"Stavnezer","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG Subclasses and Allotypes: From Structure to Effector Functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC Class I-like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The Neonatal Fc Receptor (FcRn): A Misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1469-185X.1958.tb01412.x","article-title":"The Passive Immunity of the Young Mammal","volume":"33","author":"Brambell","year":"1958","journal-title":"Biol. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Daeron, M., and Nimmerjahn, F. (2014). Fc Receptors, Springer International Publishing. Current Topics in Microbiology and Immunology.","DOI":"10.1007\/978-3-319-07911-0"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.4049\/jimmunol.166.5.3266","article-title":"MHC Class I-Related Neonatal Fc Receptor for IgG Is Functionally Expressed in Monocytes, Intestinal Macrophages, and Dendritic Cells1","volume":"166","author":"Zhu","year":"2001","journal-title":"J. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.4049\/jimmunol.1200501","article-title":"Impact of Immune Complex Size and Glycosylation on IgG Binding to Human Fc\u03b3Rs","volume":"190","author":"Lux","year":"2013","journal-title":"J. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1172\/JCI130029","article-title":"Functional Diversification of IgGs through Fc Glycosylation","volume":"129","author":"Wang","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.tips.2018.07.007","article-title":"Targeting FcRn to Generate Antibody-Based Therapeutics","volume":"39","author":"Ward","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11076","DOI":"10.1073\/pnas.0402970101","article-title":"Exocytosis of IgG as Mediated by the Receptor, FcRn: An Analysis at the Single-Molecule Level","volume":"101","author":"Ober","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5889","DOI":"10.1073\/pnas.0700337104","article-title":"Elucidation of Intracellular Recycling Pathways Leading to Exocytosis of the Fc Receptor, FcRn, by Using Multifocal Plane Microscopy","volume":"104","author":"Prabhat","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/nbt1143","article-title":"Engineering the Fc Region of Immunoglobulin G to Modulate in Vivo Antibody Levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Chen, R., J\u00e4\u00e4ttel\u00e4, M., and Liu, B. (2020). Lysosome as a Central Hub for Rewiring PH Homeostasis in Tumors. Cancers, 12.","DOI":"10.3390\/cancers12092437"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Dillon, C.F., Weisman, M.H., and Miller, F.W. (2020). Population-Based Estimates of Humoral Autoimmunity from the U.S. National Health and Nutrition Examination Surveys, 1960\u20132014. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0226516"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Martin, T.C., Ilieva, K.M., Visconti, A., Beaumont, M., Kiddle, S.J., Dobson, R.J.B., Mangino, M., Lim, E.M., Pezer, M., and Steves, C.J. (2020). Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. Cells, 9.","DOI":"10.3390\/cells9030665"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1073\/pnas.1019037108","article-title":"Neonatal Fc Receptor for IgG (FcRn) Regulates Cross-Presentation of IgG Immune Complexes by CD8\u2212CD11b+ Dendritic Cells","volume":"108","author":"Baker","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.4049\/jimmunol.181.4.2572","article-title":"The MHC Class II-Associated Invariant Chain Interacts with the Neonatal Fc\u03b3 Receptor and Modulates Its Trafficking to Endosomal\/Lysosomal Compartments","volume":"181","author":"Ye","year":"2008","journal-title":"J. Immunol."},{"key":"ref_39","unstructured":"Charles A Janeway, J., Travers, P., Walport, M., and Shlomchik, M.J. (2001). Immunobiology: The Immune System in Health and Disease, Garland Science. [5th ed.]."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"V\u00e9gh, A., Farkas, A., K\u00f6vesdi, D., Papp, K., Cervenak, J., Schneider, Z., Bender, B., Hiripi, L., L\u00e1szl\u00f3, G., and Prechl, J. (2012). FcRn Overexpression in Transgenic Mice Results in Augmented APC Activity and Robust Immune Response with Increased Diversity of Induced Antibodies. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0036286"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.0801717105","article-title":"Dependence of Antibody-Mediated Presentation of Antigen on FcRn","volume":"105","author":"Qiao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1084\/jem.192.12.1685","article-title":"Cd8+ but Not Cd8\u2212 Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo","volume":"192","author":"Lehar","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ Dendritic Cells (DCs) Represent a Unique Myeloid DC Subset That Cross-Presents Necrotic Cell Antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.coi.2010.01.022","article-title":"Intracellular Mechanisms of Antigen Cross Presentation in Dendritic Cells","volume":"22","author":"Amigorena","year":"2010","journal-title":"Curr. Opin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fimmu.2018.01643","article-title":"Current Concepts of Antigen Cross-Presentation","volume":"9","author":"Embgenbroich","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e20200359","DOI":"10.1084\/jem.20200359","article-title":"FcRn Is a CD32a Coreceptor That Determines Susceptibility to IgG Immune Complex\u2013Driven Autoimmunity","volume":"217","author":"Hubbard","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_47","unstructured":"(2023, February 11). Vyvgart-Prescribing-Information.Pdf. Available online: https:\/\/www.argenx.com\/product\/vyvgart-prescribing-information.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc Receptor Antagonist Efgartigimod Safely and Sustainably Reduces IgGs in Humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","article-title":"Randomized Phase 2 Study of FcRn Antagonist Efgartigimod in Generalized Myasthenia Gravis","volume":"92","author":"Howard","year":"2019","journal-title":"Neurology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, Efficacy, and Tolerability of Efgartigimod in Patients with Generalised Myasthenia Gravis (ADAPT): A Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia","volume":"95","author":"Newland","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2022-167838","article-title":"Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)","volume":"140","author":"Broome","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjd.20782","article-title":"Treatment of Pemphigus Vulgaris and Foliaceus with Efgartigimod, a Neonatal Fc Receptor Inhibitor: A Phase II Multicentre, Open-label Feasibility Trial","volume":"186","author":"Goebeler","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dresser, L., Wlodarski, R., Rezania, K., and Soliven, B. (2021). Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J. Clin. Med., 10.","DOI":"10.3390\/jcm10112235"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The Membrane Attack Pathway of Complement Drives Pathology in Passively Induced Experimental Autoimmune Myasthenia Gravis in Mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin. Exp. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1017\/cjn.2017.253","article-title":"Autoantibodies to Low-Density Lipoprotein Receptor-Related Protein 4 in Double Seronegative Myasthenia Gravis: A Systematic Review","volume":"45","author":"Bacchi","year":"2018","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 Autoantibodies Cause Myasthenia Gravis by Inhibiting Binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Singh, A., Uzun, G., and Bakchoul, T. (2021). Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040789"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis & Clinical Features of Pemphigus Foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol. Clin."},{"key":"ref_60","first-page":"e17889","article-title":"Differentiating Pemphigus Foliaceus From Pemphigus Vulgaris in Clinical Practice","volume":"13","author":"Stumpf","year":"2021","journal-title":"Cureus"},{"key":"ref_61","unstructured":"(2023, June 01). Patients. Available online: https:\/\/www.argenx.uk\/patients."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/6\/817\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:06Z","timestamp":1760125866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/12\/6\/817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pathogens12060817"],"URL":"https:\/\/doi.org\/10.3390\/pathogens12060817","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}